| Elbowoods Memorial Health Center | |
|
1058 College Dr, New Town, ND 58763-9112 | |
| (701) 627-4750 | |
| Not Available |
| Full Name | Elbowoods Memorial Health Center |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 1058 College Dr, New Town, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992206528 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Elbowoods Memorial Health Center 1058 College Dr, New Town, ND 58763-9112 Ph: (701) 627-4750 | Elbowoods Memorial Health Center 1058 College Dr, New Town, ND 58763-9112 Ph: (701) 627-4750 |
News Archive
ProSanos Corporation is pleased to introduce CEWorks™, an innovative analytic software application providing comparative effectiveness data on demand for professionals in the life sciences and healthcare industries. CEWorks is part of the award winning suite of software products and services offered by ProSanos for pharmacovigilance, health outcomes, and the assessment of product effectiveness.
A pair of new thin, transparent devices, constructed with soft lithography, should boost research in which nematodes are studied to explore brain-behavior connections and to screen new pharmaceuticals for potential treatment of parasitic infections in humans, report 10 scientists at three institutions.
Immune Targeting Systems (ITS) Limited, one of the leading developers of synthetic vaccines for mutating viruses, today announced the first patient has been treated in its Phase-I trial with its synthetic universal influenza vaccine (FP-01). Commencement of trials follows receipt of UK Regulatory Authority (MHRA) approval. Over the same period the company brought in £500,000 new investment from Esperante Ventures (UK).
University at Buffalo researchers have demonstrated for the first time that injecting adult bone marrow stem cells into skeletal muscle can repair cardiac tissue, reversing heart failure.
Alliqua, Inc., an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and wound care technologies today announced that it has acquired from Noble Biomaterials, Inc. a 10 year exclusive global license for two wound care dressings, with an additional 10 year renewal option.
› Verified 6 days ago